[Testing the efficacy of fluconazole in treatment of oral and throat candidiasis in patients after kidney transplantation].
Eleven kidney transplant recipients with the oral or/and throat candidiasis which occurred during the first 3 months after transplantation were studied. Fluconazole was administered orally in the dose of 50 mg each 24, 48, 72 h, according to creatinine clearance. No clinical symptoms of candidiasis on the third day of the treatment were observed. In all patients, negative mucosal cultures were noted at the 8th day after first fluconazole dose. During fluconazole was with in normal range. Furthermore, no changes in serum bilirubin alanine transaminase, lactate dehydrogenase and alkaline phosphatase activities were observed. Serum creatinine decreased during this follow-up. In the 30th day after fluconazole administration cessation the mycological evidence of Candida p. reinfection were noted in 25% of patients. Fluconazole is highly efficient and safe agent to manage the oral and throat candidiasis in renal transplant recipients.
Michnowska
M
M
Instytutu Transplantologii AM w Warszawie.
Klin
M J
MJ
Mroczka
T
T
Mularczyk
E
E
Lao
M
M
D000328:Adult; D002180:Candidiasis, Oral / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use*; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D010608:Pharyngeal Diseases / Q000188:drug therapy* / Q000209:etiology
D015725:Fluconazole
Badania skuteczności flukonazolu w leczeniu kandydozy błon śluzowych jamy ustnej i gardła u chorych po przeszczepieniu nerki.